Article

Metabolic syndromes and malignant transformation: where the twain shall meet.

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Science translational medicine (impact factor: 7.8). 10/2010; 2(54):54ps50. DOI:10.1126/scitranslmed.3001669
Source: PubMed

ABSTRACT Recurrent somatic mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes that result in the accumulation of D-2-hydroxyglutarate (D-2-HG) have been identified in malignant gliomas and in acute myeloid leukemia (AML). However, the function of this metabolite in normal and malignant tissues remains uncertain. A report in the current issue of Science describes a germline IDH2 mutation in a subset of patients with a rare metabolic disorder--D-2-hydroxyglutaric aciduria-that is similar to mutations seen in cancer patients. These observations further elucidate the effects of IDH mutations on normal and malignant cells.

0 0
 · 
0 Bookmarks
 · 
27 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

accumulation
 
acute myeloid leukemia
 
AML
 
current issue
 
D-2-HG
 
germline IDH2 mutation
 
IDH mutations
 
IDH2 genes
 
isocitrate dehydrogenase 1
 
malignant gliomas
 
malignant tissues
 
metabolite
 
mutations
 
observations
 
Recurrent somatic mutations
 
uncertain
 

Neha Bhagwat